Literature DB >> 33218938

AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis.

Long Zheng1, Shanshan Li2, Xianghong Zheng1, Rong Guo1, Wei Qu3.   

Abstract

Papillary thyroid cancer (PTC) is the most prevalent endocrine tumor, and its incidence is still increasing. The mechanisms of PTC dedifferentiation and malignant progression remain unclear. In this study, we identified AHNAK2 as a key gene in PTC by differential expression analysis among four GEO datasets and validated its overexpression profile by data from the Oncomine, TCGA, and HPA databases and IHC staining analysis. AHNAK2 upregulation significantly correlated with advanced grades, stages, and lymph node events. Survival analysis suggested that AHNAK2 overexpression was coupled with poor overall survival. The immune infiltration analysis by TIMER and CIBERSORT indicated that AHNAK2 expression tightly correlated with the infiltration of diverse immune cell types, especially T cell subtypes. In addition, AHNAK2 is correlated with the expression of other conventional key genes of TC, such as PIK3CA, MAPK1, CTNNB1, and SLC5A5. AHNAK2 may be a novel prognostic marker for PTC.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AHNAK2; Bioinformatic analysis; GEO; Immune infiltration; Papillary thyroid cancer

Mesh:

Substances:

Year:  2020        PMID: 33218938     DOI: 10.1016/j.intimp.2020.107185

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

1.  Establishment and Validation of an Interferon-Stimulated Genes (ISGs) Prognostic Signature in Pan-cancer Patients: A Multicenter, Real-world Study.

Authors:  Zheng Zhou; Yujia Zheng; Shaobo Mo; Shuofeng Li; Xinlei Zheng; Ran Wei; Tao Fan; Tianli Chen; Chu Xiao; Chunxiang Li; Jie He
Journal:  Int J Biol Sci       Date:  2022-05-21       Impact factor: 10.750

2.  Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes.

Authors:  Tingbo Ye; Leilei Lin; Lulu Cao; Weiguo Huang; Shengzhe Wei; Yunfeng Shan; Zhongjing Zhang
Journal:  Front Oncol       Date:  2022-05-23       Impact factor: 5.738

Review 3.  The Obscure Potential of AHNAK2.

Authors:  Mohamed Zardab; Konstantinos Stasinos; Richard P Grose; Hemant M Kocher
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

4.  Construction of a Redox-Related Prognostic Model with Predictive Value in Survival and Therapeutic Response for Patients with Lung Adenocarcinoma.

Authors:  Lingyan Xiao; Qian Li; Yongbiao Huang; Zhijie Fan; Li Ma; Bo Liu; Xianglin Yuan
Journal:  J Healthc Eng       Date:  2022-02-25       Impact factor: 2.682

5.  High Expression of THBS1 Leads to a Poor Prognosis in Papillary Thyroid Cancer and Suppresses the Anti-Tumor Immune Microenvironment.

Authors:  Anqi Jin; Jin Zhou; Pengcheng Yu; Shichong Zhou; Cai Chang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Pyroptosis-Related Patterns Predict Tumor Immune Landscape and Immunotherapy Response in Bladder Cancer.

Authors:  Yilin Yan; Xiangqian Cao; Zeyi Wang; Zhengnan Huang; Jinming Cai; Pengfei Tang; Chenkai Yang; Fang Zhang; Shujie Xia; Bing Shen
Journal:  Front Mol Biosci       Date:  2022-04-26

7.  Association between hashimoto thyroiditis and differentiated thyroid cancer: A single-center experience.

Authors:  Federico Cappellacci; Gian Luigi Canu; Maria Letizia Lai; Eleonora Lori; Miriam Biancu; Francesco Boi; Fabio Medas
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.